Claritas Genomics Inc Cambridge, MA - 02139

Claritas Genomics Inc is categorized under Radiation Dosimetry Laboratory in Cambridge, MA and active since 2013.

Claritas Genomics Inc was established in 2013, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Radiation Dosimetry Laboratory business, which does work in the B2B market, and is classified as a Radiation Dosimetry Laboratory, under code number 541380 by the NAICS.

If you are seeking more information, feel free to contact Mary Ellen Cortizas at the company’s single location by writing to 99 Erie St, Cambridge, Massachusetts MA 02139 or by phoning (617) 355-6347. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Claritas Genomics Inc
Contact Person: Mary Ellen Cortizas
Address: 99 Erie St, Cambridge, Massachusetts 02139
Phone Number: (617) 355-6347
Website Address: claritasgenomics.com
Annual Revenue (USD): $1.000.000 to $2.499.999
Founded: 2013
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Radiation Dosimetry Laboratory
SIC Code: 8734
NAICS Code: 541380
Share This Business:

Claritas Genomics Inc was started in 2013 to provide professional Radiation Dosimetry Laboratory under the SIC code 8734 and NAICS code 541380. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.

Feel free to contact Mary Ellen Cortizas for inquiries that concern Claritas Genomics Inc by calling the company number (617) 355-6347, as your correspondence is most welcome. Additionally, the physical location of the single location of Claritas Genomics Inc can be found at the coordinates as well as the street address 99 Erie St in Cambridge, Massachusetts 02139.

For its online presence, you may visit Claritas Genomics Inc’s website at claritasgenomics.com and engage with its social media outlets through on Twitter and on Facebook.